Dear Editor, Data on the long-term management of patient receiving adalimumab for hidradenitis suppurativa (HS) are scarce and mainly derived from the period 2 of the PIONEER studies (Alexa B Kimball et al. 2016; Theut Riis, Thorlacius, and Jemec 2018; Alexa B Kimball et al. 2012). The aim of our retrospective study was to review epidemiological data and analyze the therapeutic response, adverse effects, duration, and reasons of short suspension periods (SSP) during long-term antiTNFα therapy, in a real-life setting.
No takes yet. Share an insight, caveat, or question.
Bettoli et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: